(2S)-2-methyl-N-((S)-1-phenylethyl)octanamide | 128342-66-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2S)-2-methyl-N-((S)-1-phenylethyl)octanamide
• 英文别名: (2S)-2-methyl-N-[(1S)-1-phenylethyl]octanamide
• CAS: 128342-66-5
• 化学式: C₁₇H₂₇NO
• 分子量: 261.407
• InChiKey: NAOHHIFURMZXQZ-GJZGRUSLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (2R)-2-methyl-N-((S)-1-phenylethyl)octanamide 生成 (2S)-2-methyl-N-((S)-1-phenylethyl)octanamide
  参考文献：
  名称：

  NOVEL ANTI-PARASITIC COMPOUNDS

  摘要：

  一种新型的高度N-甲基化线性脂肽化合物结构类，可用于治疗寄生虫病。

  公开号：

  US20120108502A1

文献信息

• Further novel anti-parasitic compounds
  申请人：Linington Roger

  公开号：US09321811B2

  公开（公告）日：2016-04-26

  A novel structural class of highly N-methylated linear lipopeptide compounds useful for the treatment of parasitic disease.

  一种新型的高度N-甲基化线性脂肽化合物结构类，可用于治疗寄生虫病。
• Anti-parasitic compounds
  申请人：Linington Roger

  公开号：US08772247B2

  公开（公告）日：2014-07-08

  A novel structural class of highly N-methylated linear lipopeptide compounds useful for the treatment of parasitic disease.

  一种新型的高度N-甲基化的线性脂肽化合物结构类，适用于治疗寄生虫病。
• FURTHER NOVEL ANTI-PARASITIC COMPOUNDS
  申请人：Linington Roger

  公开号：US20140221276A1

  公开（公告）日：2014-08-07

  A novel structural class of highly N-methylated linear lipopeptide compounds useful for the treatment of parasitic disease.

  一种新型的高度N-甲基化线性脂肽化合物结构类，可用于治疗寄生虫病。
• ANTI-TRYPANOSOME COMPOUNDS AND TREATMENTS
  申请人：Linington Roger

  公开号：US20160206680A1

  公开（公告）日：2016-07-21

  A novel structural class of highly N-methylated linear lipopeptide compounds useful for the treatment of parasitic disease.

  一种新型结构类高度N-甲基化的线性脂肽化合物，可用于治疗寄生虫病。
• Almiramides A−C: Discovery and Development of a New Class of Leishmaniasis Lead Compounds
  作者：Laura M. Sanchez、Dioxelis Lopez、Brian A. Vesely、Gina Della Togna、William H. Gerwick、Dennis E. Kyle、Roger G. Linington

  DOI：10.1021/jm100265s

  日期：2010.5.27

  Leishmaniasis is a debilitating disease caused by protozoan parasites of the genus Leishmania, which affects an estimated 12 million people worldwide. The discovery of new lead compounds for leishmaniasis is therefore a pressing concern for global health programs. The organic extract of a Panamanian collection of the marine cyanobacterium Lyngbya majuscula showed strong in vitro activity in two complementary screens against the tropical parasite Leishmania donovani, the causative agent of visceral leishmaniasis. Chromatographic separation of this complex mixture led to the isolation of the highly N-methylated linear lipopeptides, almiramides A-C (1-3). Comparison with the biological activities of a number of related metabolites and semisynthetic derivatives revealed key features required for activity and afforded one new compound (11) with superior in vitro activity. Subsequent synthesis of a library of simplified analogues led to the discovery of several compounds with improved therapeutic indices to the natural products.